Emily Faucette has more than 25 years of healthcare communications experience across corporate, product and investor relations. Prior to joining Talis Biomedical in 2021, Ms. Faucette served as Senior Vice President of Global Corporate Affairs & Investor Relations at Portola Pharmaceuticals, where she was responsible for integrated global communications, including public relations, patient advocacy and investor relations. She also led the communications strategy to represent Portola’s point of view in the announcement of and integration for an acquisition by Alexion Pharmaceuticals that closed in July 2020. Prior to Portola, Ms. Faucette spent 13 years at Genomic Health up to its acquisition by Exact Sciences for $3B in 2019. While at Genomic Health, she helped establish and expand a best-in-class global communications team that led public relations, investor relations, patient advocacy, corporate, product and employee communications, digital marketing, and branding. Ms. Faucette began her career in the healthcare communications agency setting with ten years of experience between WeissComm Partners (now Real Chemistry) and Ketchum. Ms. Faucette earned a B.A. in public communications from American University.